UnknownNot Applicable

Validation of a Tear-based Screening Assay for Breast Cancer

United States205 participantsStarted 2021-06-01

Plain-language summary

This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms. This tear-based screening test was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

Who can participate

Age range18 Years – 100 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Female over the age of 18 Able to undergo the informed consent process Willingness to comply with all study procedures Exclusion Criteria: Currently diagnosed or are receiving treatment for breast cancer Have an active eye infection under 18 years of age

What they're measuring

Validation of a tear-based biological test

Timeframe: 3 years

Trial details

NCT IDNCT04928014

SponsorNamida Lab

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Healthy trials